Washington, D.C.

D.C. Vape Crackdown Blinks As FDA Gives Some Makers A Temporary Pass

AI Assisted Icon
Published on May 09, 2026
D.C. Vape Crackdown Blinks As FDA Gives Some Makers A Temporary PassSource: Unsplash/ E-Liquids UK

Washington’s long-running war on vapes just shifted tactics. The Food and Drug Administration on May 8 rolled out new guidance saying it will, in a narrow slice of cases, step back from aggressive enforcement against certain unauthorized e‑cigarettes and nicotine pouches while their marketing applications are under scientific review. The move offers temporary breathing room to companies whose premarket applications or supplemental filings have been accepted and sitting in the agency’s queue for a long stretch. FDA officials stressed the shift is tightly limited and that anything likely to lure kids remains squarely in their enforcement crosshairs.

What the guidance does

Under the guidance, FDA says it generally does not intend to prioritize enforcement against electronic nicotine delivery systems (ENDS) and nicotine pouch products that meet several conditions. The products must be covered by a premarket tobacco product application (PMTA) that has been accepted and filed or a supplemental PMTA (sPMTA) that has been accepted and pending for more than 180 days. For non‑tobacco flavored ENDS, the application must also include the data FDA needs to evaluate whether the product protects public health.

The guidance also lays out clear “do not cross” lines. Presumptive red flags that could still trigger enforcement include the use of cartoon‑style characters, devices disguised as toys or phones, unusually high nicotine levels, or any lack of child‑resistant packaging. “By not prioritizing these tobacco products for enforcement, FDA will be able to better allocate its enforcement resources,” the agency writes, according to FDA.

Industry and political backdrop

The shift follows months of pressure from the industry and from the White House for clearer and faster review pathways. News outlets report that major tobacco companies with products already in FDA’s pipeline could be among those that stand to benefit. Reuters reported that the policy change could help manufacturers whose filings have been accepted for review, and the timing comes on the heels of a separate May 5 decision that authorized a small set of flavored e‑cigarette products for adult smokers, a move that drew fire from public‑health advocates. Per reporting by AP, industry lobbyists say the new guidance gives them a clearer path while scientific review continues.

What it means for shops and consumers

For vape shops and customers, this is not a free pass. Products covered by the guidance are still technically unauthorized, and FDA says it can move against them at any time if safety issues surface or if a product appears likely to appeal to youth. The agency plans to create and maintain a public webpage that will list manufacturers and products it generally does not intend to prioritize for enforcement, and it is urging companies to work with their regulatory health project manager if they hope to appear on that roster.

FDA says this approach will let inspectors and enforcement partners focus more squarely on illicit imports and the products that pose the greatest risks while formal scientific reviews keep grinding forward, according to the FDA Center for Tobacco Products.

Next steps and legal caveats

The guidance takes effect immediately, but it will also be published in the Federal Register and is open for public comment. FDA is careful to say the document reflects its “current thinking,” not a binding rulebook or permanent amnesty. Federal auditors and state regulators have already documented how widespread illicit imports and enforcement challenges have become, and FDA says it will keep working with agencies such as Customs and Border Protection and the Department of Justice to target clearly illegal products.

Manufacturers that want to lean on the new policy are advised to make sure their PMTAs and supplemental filings are complete and contain the detailed composition, risk information, and device data FDA says it needs for scientific review. For more on the backdrop and enforcement history, see the Federal Register notice and a recent Government Accountability Office report. Federal Register, GAO.